However, 2025 isn't exactly around the corner, and Trikafta -- by far Vertex's most important drug to date, which already accounts for the bulk of its revenue -- likely won't lose patent protection until well into the 2030s.In 2013, the company started offering leasing arrangements, which gives its customers more flexibility in how they pay for the da Vinci system.